Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alvotech
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
September 25, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Changes to the Leadership Team
September 05, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
August 29, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 22, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
JNJ
TEVA
Alvotech to Participate in Jefferies Healthcare Conference
May 31, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
May 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
May 19, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
May 17, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Issues Annual Equality Report Covering 2022
May 15, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 19, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.